Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

25 Phase II Trial of Sacituzumab Tirumotecan in Patients with SMARCB1-Deficient Renal Medullary Carcinoma Previously Treated with at Least One Prior Line of Therapy: STaRMC Trial (NCT07438626)

Abstract Background SMARCB1-deficient renal medullary carcinoma (RMC) is a highly aggressive renal cell carcinoma (RCC) that predominantly affects young individuals of African descent harboring sickle hemoglobinopathies (Msaouel et al. Clin Cancer Res 2018, PMID: 29440190). All cases are defined by loss of the SMARCB1...

P. Msaouel, Rebecca S. Slack-Tidwell, R. Sheth et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.